Registry for patients with cutaneous lupus
Official title: Molecular Studies on Cutaneous Lupus
Run by University of Texas Southwestern Medical Center · NCT01266915 · Data updated 2026-11-12
This study is creating a national registry for people with cutaneous lupus to collect information that will help understand the condition better and improve how it's diagnosed and managed.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | University of Texas Southwestern Medical Center Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Status | Recruiting |
| Started | January 2009 |
| Main results expected | December 2030 |
| Study ends | December 2030 |
| Registry record updated | November 26, 2025 |
| Trial ID | NCT01266915 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults diagnosed with cutaneous lupus erythematosus or systemic lupus erythematosus who can provide informed consent.
✕Probably not a fit
Patients under 18 years of age or those whose cutaneous lupus resolves with medication may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to create a national registry for individuals diagnosed with cutaneous lupus erythematosus and systemic lupus erythematosus. By collecting comprehensive data, including medical histories, clinical information, and biological samples, the study seeks to better understand the causes and improve the diagnosis and management of cutaneous lupus. Participants will complete questionnaires and provide blood and skin samples, with follow-ups conducted annually for five years. The study does not involve any treatments but will inform participants about relevant clinical trials.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of cutaneous lupus, enhancing the quality of life for patients.
How similar studies have gone: While there have been smaller genetic studies on cutaneous lupus, this registry approach is novel and aims to gather a larger patient population for more comprehensive insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with cutaneous lupus erythematosus and/or systemic lupus erythematosus by clinical, laboratory, and histopathological findings * Ability to speak and read English or Spanish at a 6th grade reading level (a translator will be available with additional consent forms in Spanish) * Ability to give written informed consent Exclusion Criteria: * Less than 18 years of age, since the characteristics of the disease in these subjects could be very different * Due to a medication, in which its discontinuation results in the resolution of cutaneous lupus, since the characteristics of the disease in these subjects could be very different * Medical conditions who do not warrant a skin biopsy * Unable to give written, informed consent or undergo a skin biopsy and/or venipuncture for any other reason
Where it's running
-
University of Texas Southwestern Medical Center Dallas
Dallas, Texas, United States Recruiting
Study contacts
- Study coordinator: Benjamin Chong, MD, MSCS
- Email: skinlupus.registry@utsouthwestern.edu
- Phone: 214-648-3427
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Immune signals and regulatory T cells in migraine
This research will test whether blood immune markers and regulatory T cells are linked to migraine in women ages 18–50 who have migraine or certain autoimmune/inflammatory conditions.
-
Collection of biological samples to study systemic autoimmune diseases
This study is collecting samples from people with autoimmune diseases like lupus and scleroderma to see if they can find new ways to diagnose and treat these conditions better.
-
Using stem cells to treat lupus nephritis
This study is testing if bone marrow stem cells can help adults with lupus nephritis who haven't responded well to regular treatments feel better.
-
Evaluating belimumab for early lupus treatment
This study is testing if the drug belimumab can help people who have been diagnosed with lupus in the last two years feel better and possibly stay in remission.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.